January 5, 2017 / 3:22 PM / 2 years ago

BUZZ-U.S. STOCKS ON THE MOVE-Retailers, CEB, CTi Biopharma, Otonomy

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, here ; for the Morning News Call newsletter, here ) U.S. stocks were little changed on Thursday as a drop in banks and discretionary stocks were offset by gains in technology names.

Dow Jones industrial average futures were up 0.01 percent at 19,857, S&P 500 futures were down 0.02 percent at 2,263.75 and Nasdaq 100 futures were up 0.44 percent at 4,955.

** MACY’S INC, $30.67, -14.43 pct

** KOHL’S CORP, $42.56, -17.96 pct

** J C PENNEY CO INC, $7.845, -17.96 pct

** NORDSTROM INC, $44.69, -8.65 pct

** GAP INC, $23.17, -4.26 pct

** ABERCROMBIE & FITCH CO, $12.28, -4.21 pct

Department store chains Macy’s and Kohl’s cut their 2016 profit forecasts, after holiday season sales fell more than expected.

Other retailers were also down sharply.

** CTI BIOPHARMA CORP, $4.8743, +22.78 pct

The drug developer said the U.S. FDA has removed full clinical hold on its experimental blood cancer drug, pacritinib.

** CEB INC, $75.3, +21.65 pct

** GARTNER INC, $94.51, -7.15 pct

IT research and advisory company Gartner said it would buy CEB, a provider of business research and analysis, in a cash-and-stock deal valued at $2.6 billion to expand its business globally.

** SEARS HOLDINGS CORP, $10.76, +3.86 pct

** STANLEY BLACK & DECKER INC, $118.98, +2.15 pct

Power tool maker Stanley Black & Decker said it agreed to buy Sears Holdings Corp’s Craftsman tool brand for $900 million in cash.

** EVOKE PHARMA INC, $2.9103, +8.19 pct

Rodman & Renshaw raised its rating and price target on the stock.

** OTONOMY INC, $18.02, +11.23 pct

The company said its drug to treat acute otitis externa, an infection in the outer ear canal, met the main goal in a late-stage trial.

** PIERIS PHARMACEUTICALS, $1.85, +25.86 pct

The company announced a collaboration in immunology with France-based Servier.

** HALOZYME THERAPEUTICS INC, $11.65, +8.98 pct

Halozyme said its flagship drug delivery technology in tandem with therapies from Celgene Corp and Eli Lilly and Co succeeded in a mid-stage study involving patients with an advanced form of pancreatic cancer.

** ALEXION PHARMACEUTICALS INC, $137.56, +8.22 pct

The drugmaker see no need to restate previously issued results, following an investigation related to sales practices of its blood disorder drug, Soliris.

** CESCA THERAPEUTICS INC, $3.65, -0.55 pct

The company announced FDA approval of IDE supplement for Phase III clinical trial.

** AETERNA ZENTARIS INC, $2.5, -31.51 pct

The Canadian drug developer’s experimental test to diagnose adult growth hormone deficiency (AGHD) failed late-stage study.

** HERON THERAPEUTICS INC, $13.225, -4.17 pct

Heron on Wednesday said its experimental combination drug for post-operative pain led to significant reductions in pain intensity and the need for opioids, according to initial data from a mid-stage trial.

At least two brokerages cut their price targets on the stock.

** AMAZON.COM INC, $772.8721, +2.07 pct

The online retailer and teen apparel store chain Forever 21 Inc are among the companies weighing offers to acquire bankrupt American Apparel LLC, people familiar with the talks said on Wednesday. (Compiled by Rishika Sadam in Bengaluru; Editing by Maju Samuel)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below